AbbVie Inc. (ABBV)

78.25
0.40 0.51
NYSE : Health Technology
Prev Close 78.65
Open 78.88
Day Low/High 77.01 / 79.20
52 Wk Low/High 73.81 / 100.23
Volume 5.43M
Avg Volume 5.21M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 116.33B
EPS 3.70
P/E Ratio 21.98
Div & Yield 4.28 (5.14%)

Latest News

New Two-Year Data At The 24th World Congress Of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance

New Two-Year Data At The 24th World Congress Of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance

- Longer-term results from IMMhance showed 73 percent and 72 percent of patients treated with continuous SKYRIZI™ (risankizumab) experienced complete skin clearance (defined as sPGA 0 and PASI 100, respectively) at week 94, among patients who achieved sPGA 0/1 at week 28 [1]

AbbVie To Present At The Goldman Sachs Global Healthcare Conference

AbbVie To Present At The Goldman Sachs Global Healthcare Conference

NORTH CHICAGO, Ill., June 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 40 th Annual Global Healthcare Conference on Wednesday, June 12, 2019.

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

AbbVie Presents Data From Venetoclax Chemotherapy-Free Combination Regimen For Patients With Previously Untreated Chronic Lymphocytic Leukemia

AbbVie Presents Data From Venetoclax Chemotherapy-Free Combination Regimen For Patients With Previously Untreated Chronic Lymphocytic Leukemia

-  Phase 3 data from CLL14 study were highlighted in an oral presentation (abstract #7502) today at ASCO and published in the New England Journal of Medicine -  Patients treated with venetoclax plus obinutuzumab lived significantly longer without their...

AbbVie Presents Results From Several Studies And Clinical Trials Investigating Medicines Across More Than 15 Cancers At The 2019 ASCO And EHA Meetings

AbbVie Presents Results From Several Studies And Clinical Trials Investigating Medicines Across More Than 15 Cancers At The 2019 ASCO And EHA Meetings

- AbbVie to present more than 40 abstracts from its oncology pipeline at this year's ASCO and EHA medical meetings in June

Going in Circles

We can't get a break under all those round numbers on the major indexes, yet, the Russell 2000 outperforms and the number of stocks making new lows mostly stays put.

Gilead Sciences Slips on Goldman's Downgrade to Sell

Gilead Sciences Slips on Goldman's Downgrade to Sell

Shares of Gilead Sciences fall after Goldman Sachs downgrades the stock to sell from neutral.

AbbVie Provides Update On Depatuxizumab Mafodotin (Depatux-M), An Investigational Medicine For Newly Diagnosed Glioblastoma, An Aggressive Form Of Brain Cancer

AbbVie Provides Update On Depatuxizumab Mafodotin (Depatux-M), An Investigational Medicine For Newly Diagnosed Glioblastoma, An Aggressive Form Of Brain Cancer

-Phase 3 INTELLANCE-1 study, conducted in collaboration with the RTOG Foundation, did not meet primary endpoint of overall survival at the interim analysis and demonstrated no survival benefit for patients receiving Depatux-M

Aurora Cannabis Up 2.4%; Tera Tech Off 5.6%: Cannabis Stocks Mixed

Aurora Cannabis Up 2.4%; Tera Tech Off 5.6%: Cannabis Stocks Mixed

Gainers trail losers in Cannabis sector action Thursday.

MC10, Inc. And AbbVie (NYSE:ABBV) Announce Clinical Trials In Multiple Sclerosis Using The BioStamp NPoint® System

MC10, Inc. And AbbVie (NYSE:ABBV) Announce Clinical Trials In Multiple Sclerosis Using The BioStamp NPoint® System

MC10, Inc., a healthcare technology company specializing in wearable digital health sensors, and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the companies are working together on clinical trials designed to...

AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation With Boehringer Ingelheim

AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation With Boehringer Ingelheim

NORTH CHICAGO, Ill., May 14, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that it has resolved U.

AbbVie To Present At The UBS Global Healthcare Conference

AbbVie To Present At The UBS Global Healthcare Conference

NORTH CHICAGO, Ill., May 14, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 21, 2019.

AbbVie To Present At The Bank Of America Merrill Lynch Healthcare Conference

AbbVie To Present At The Bank Of America Merrill Lynch Healthcare Conference

NORTH CHICAGO, Ill., May 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019.

European Commission Approves SKYRIZI™ (risankizumab) For The Treatment Of Moderate To Severe Plaque Psoriasis

European Commission Approves SKYRIZI™ (risankizumab) For The Treatment Of Moderate To Severe Plaque Psoriasis

- Approval based on results from clinical studies showing high rates of skin clearance at 16 weeks; this clearance was durable at one year with every 12-week dosing[1-4]

AbbVie To Present New And Updated Data Of Investigational Medicines For Parkinson's Disease And Multiple Sclerosis At 2019 American Academy Of Neurology Annual Meeting

AbbVie To Present New And Updated Data Of Investigational Medicines For Parkinson's Disease And Multiple Sclerosis At 2019 American Academy Of Neurology Annual Meeting

- Presentations include updates on ABBV-951, a subcutaneous infusion therapy for Parkinson's disease (PD), and elezanumab, a monoclonal antibody directed against repulsive guidance molecule A (RGMa) in multiple sclerosis (MS), among other data to be presented

AbbVie Climbs Earnings Beat, Guidance Boost

AbbVie Climbs Earnings Beat, Guidance Boost

AbbVie climbs after beating first-quarter estimates and raising full-year guidance.

Earnings, Earnings and More Earnings, Facebook Results: Market Recon

Earnings, Earnings and More Earnings, Facebook Results: Market Recon

As we have seen so far, in terms of market reaction, there is great reward at the point of sale in beating expectations.

AbbVie Reports First-Quarter 2019 Financial Results

AbbVie Reports First-Quarter 2019 Financial Results

- Reports First-Quarter Diluted EPS of $1.65 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 14.4 Percent

Microsoft, Facebook, Tesla, Amazon and Deutsche Bank - 5 Things You Must Know

Microsoft, Facebook, Tesla, Amazon and Deutsche Bank - 5 Things You Must Know

U.S. stock futures trade mixed on Thursday; Amazon, Intel and Comcast report earnings; Microsoft jumps as third-quarter earnings beat analysts' expectations; Facebook sets aside $3 billion for expected fine from Federal Trade Commission.

AbbVie Expands Immunology Portfolio In The U.S. With FDA Approval Of SKYRIZI™ (risankizumab-rzaa) For Moderate To Severe Plaque Psoriasis

AbbVie Expands Immunology Portfolio In The U.S. With FDA Approval Of SKYRIZI™ (risankizumab-rzaa) For Moderate To Severe Plaque Psoriasis

- Approval based on clinical trials showing people treated with SKYRIZI™ (risankizumab-rzaa) every 12 weeks - four doses a year after two initial doses - achieved high levels of durable skin clearance at 16 weeks and maintained this response at one year[1-3]

Health Canada Approves SKYRIZI™ (risankizumab) For The Treatment Of Moderate To Severe Plaque Psoriasis

Health Canada Approves SKYRIZI™ (risankizumab) For The Treatment Of Moderate To Severe Plaque Psoriasis

SKYRIZI™(risankizumab)  is  a novel, humanized immunoglobulin monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit to treat moderate to severe plaque psoriasis 1 .

Are These Stocks the Best of the Best?

Are These Stocks the Best of the Best?

Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.

Bullish Start to Earnings: Cramer's 'Mad Money' Recap (Friday 4/12/19)

Bullish Start to Earnings: Cramer's 'Mad Money' Recap (Friday 4/12/19)

Jim Cramer says this positive start will be hard to sustain this earnings season. He's got your game plan for next week.

Square, Cabot Oil & Gas, AbbVie: 'Mad Money' Lightning Round

Square, Cabot Oil & Gas, AbbVie: 'Mad Money' Lightning Round

Jim Cramer weighs in on Square, Cabot Oil & Gas, AbbVie, Philip Morris International, Bunge, Greenbrier Companies, LCI Industries and more.

AbbVie To Host First-Quarter 2019 Earnings Conference Call

AbbVie To Host First-Quarter 2019 Earnings Conference Call

NORTH CHICAGO, Ill., April 3, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its first-quarter 2019 financial results on Thursday, April 25 before the market opens.

AbbVie Provides Update On VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program

AbbVie Provides Update On VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program

NORTH CHICAGO, Ill., March 19, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.

TheStreet Quant Rating: B- (Buy)